Answers are grounded in this paper and cite their sources.
Tests simultaneous glucose and ketone monitoring in a porcine model, suggesting promising feasibility.
Introduction and Objective: CGMs help millions of people manage their diabetes. However, no device currently measures both glucose and ketones simultaneously (e.g., to monitor the risk of DKA). IMS has developed the CGM+ system to provide multisensor, multimodal, and multianalyte data. It uses a semiconductor microsensor to generate digital multiplexed signals within the tissue, which are then transmitted to a wearable device, which forwards the data to a smartphone via BLE. We have previously validated the system in the laboratory, in preclinical studies, and in humans for glucose monitoring. This study aimed to test the feasibility of simultaneous in vivo glucose and ketone sensing. Methods: The sensor was coated with glucose oxidase and 3-HBDH enzymes to measure glucose and ketones, respectively, and was tested as a wearable device in a porcine model. Reference readings were obtained from a Contour fingerstick meter (glucose reference) and a Nova Max meter (ketones reference). Intravenous injections were used to create ketones and glucose excursions. One-point calibration was used. Results: The study showed that CGM+ can accurately track reference glucose and ketone values over multiple days (3 days in this study, limited by the study duration), as shown in Figure 1 (day 3 data). Conclusion: These results demonstrate the in vivo feasibility of simultaneously monitoring glucose and ketones using an integrated microsensor-based wearable device (CGM+). Further work is ongoing. Disclosure M. Mujeeb-U-Rahman: None. S. Islam: None. M. Babar: None. A. Muhammad Ashfaq Nadir: None. M. Honarvar nazari: None. J. Heithaus: None.
No takes yet. Share an insight, caveat, or question.
Mujeeb-U-Rahman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: